Elanco CFO awarded stock and options

Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported equity awards that increase his stake in the company.

Rhea-AI Filing Summary

Elanco Animal Health EVP and CFO Robert M. VanHimbergen reported equity awards that increase his stake in the company. He received an employee stock option grant for 48,375 shares at a price of $0.0000 per share and a separate grant of 23,675 shares of common stock, both classified as grant or award acquisitions.

According to the disclosure, the stock options vest one-third on March 1, 2027, one-third on March 1, 2028, and the remainder on March 1, 2029. The restricted stock units underlying the common stock grant vest on the same schedule. After the common stock grant, his directly held common stock position is 148,652 shares, which includes 744 shares acquired under the company’s employee stock purchase plan on January 31, 2026.

Insider Trade Summary

Grant/Award: 72,050 shares

Grant/Award 2 txns

Insider VanHimbergen Robert M

Role EVP and CFO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	48,375	$0.00	$0.00
Grant/Award	Common Stock	23,675	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 48,375 contracts (Direct); Common Stock — 148,652 shares (Direct)

Footnotes (3)

1. F1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.
2. F2. Includes 744 shares acquired under Elanco Animal Health Inc.'s Employee Stock Purchase Plan on January 31, 2026.
3. F3. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Elanco (ELAN) EVP and CFO Robert VanHimbergen report in this Form 4?

He reported equity awards that increased his holdings. The filing shows grants of employee stock options and common stock, both treated as grant or award acquisitions, rather than open-market purchases or sales, reflecting part of his executive compensation package.

How many stock options did Elanco (ELAN) grant to Robert VanHimbergen?

He was granted 48,375 employee stock options with a stated price of $0.0000 per share. These options are part of his compensation and vest over three years, rather than being acquired through open-market buying on a stock exchange.

How many Elanco (ELAN) common shares were granted to Robert VanHimbergen?

He received a grant of 23,675 shares of common stock. The filing classifies this as a grant or award acquisition, not an open-market purchase, and it contributes to his updated total direct ownership position in Elanco common stock.

What is the vesting schedule for Robert VanHimbergen’s Elanco equity awards?

Both the restricted stock units and stock options vest in three equal parts. One-third vests on March 1, 2027, another third on March 1, 2028, and the remaining portion vests on March 1, 2029, contingent on continued service.

What is Robert VanHimbergen’s Elanco (ELAN) share ownership after these grants?

After the common stock grant, he directly holds 148,652 Elanco common shares. This figure includes 744 shares acquired under Elanco’s Employee Stock Purchase Plan on January 31, 2026, in addition to the newly reported award shares.

Are the Elanco (ELAN) Form 4 transactions open-market buys or sales?

No, the transactions are classified as grant or award acquisitions under code A. They represent compensation-related grants of stock options and common stock to the EVP and CFO, rather than discretionary open-market buying or selling activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VanHimbergen Robert M

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		23,675(1)	A	$0	148,652(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$26.4	03/01/2026		A		48,375		(3)	03/01/2036	Common Stock	48,375	$0	48,375	D

Explanation of Responses:

1. Grant of restricted stock units vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

2. Includes 744 shares acquired under Elanco Animal Health Inc.'s Employee Stock Purchase Plan on January 31, 2026.

3. Grant of stock options vesting as follows: one-third vesting on March 1, 2027, one-third vesting on March 1, 2028, and the remaining vesting on March 1, 2029.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Robert M. VanHimbergen	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.